Kazia Therapeutics Ltd. KZIA
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in Kazia Therapeutics Limited's annual report to the U.S. Securities and Exchange Commission, filed 7 November 2025. Every sentence was checked against that document before publication.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
The 10-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue AUD B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ | 0.0 | 0.0 | 0.0 |
| Operating income AUD B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| EBITDA AUD B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax AUD B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | ◌ |
| Net income AUD B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow AUD B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | −0.0 | −0.0 |
| EPS, diluted AUD | −0.04 | −0.10 | −0.11 | −0.19 | −0.07 | −0.17 | −17.86 | −12.48 | −2.28 | −2.82 |
| Dividend / sh AUD | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — |
| ROE % | — | — | −135.0 | −89.1 | −32.4 | −88.0 | −61.4 | −27.1 | −36.0 | −35.6 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 6 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015.